Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Eisai CFO Casts Oncology Pipeline Expansion as Urgent Task
Eisai views the expansion of its oncology development pipeline as an urgent management priority, Chief Financial Officer and Chief IR Officer Takuya Oyama said at the company’s earnings briefing on February 9. Oyama pointed to Eisai’s recent moves to bolster…
To read the full story
Related Article
- Eisai Snares Japan Commercial Rights to Henlius’ PD-1 Inhibitor
February 6, 2026
- Eisai Picks Up Rights to Nuvation’s Taletrectinib in Europe, Other Regions
January 14, 2026
BUSINESS
- Pfizer, ASKA to Co-Promote RSV Vaccine Abrysvo in Japan
March 9, 2026
- Towa Broadens Label for Tacrolimus in Cell Transplantation
March 9, 2026
- Japan Ethical Drug Sales Up 1.2% in January: Crecon
March 9, 2026
- Positive Price Revisions Seen at Several Firms in FY2026 Reform: Poll
March 6, 2026
- Japan Grants First-Ever Approval to iPSC-Based Therapies
March 6, 2026
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…